Literature DB >> 15928809

Emodin inhibits tumor cell migration through suppression of the phosphatidylinositol 3-kinase-Cdc42/Rac1 pathway.

Q Huang1, H-M Shen, C-N Ong.   

Abstract

Enhanced cell migration is one of the underlying mechanisms in cancer invasion and metastasis. Therefore, inhibition of cell migration is considered to be an effective strategy for prevention of cancer metastasis. We found that emodin (3-methyl-1,6,8-trihydroxyanthraquinone), an active component from the rhizome of Rheum palmatum, significantly inhibited epidermal growth factor (EGF)- induced migration in various human cancer cell lines. In the search for the underlying molecular mechanisms, we demonstrated that phosphatidylinositol 3-kinase (PI3K) serves as the molecular target for emodin. In addition, emodin markedly suppressed EGF-induced activation of Cdc42 and Rac1 and the corresponding cytoskeleton changes. Moreover, emodin, but not LY294002, was able to block cell migration in cells transfected with constitutively active (CA)-Cdc42 and CA-Rac1 by interference with the formation of Cdc42/Rac1 and the p21-activated kinase complex. Taken together, data from this study suggest that emodin inhibits human cancer cell migration by suppressing the PI3K-Cdc42/Rac1 signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15928809     DOI: 10.1007/s00018-005-5050-2

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  28 in total

Review 1.  Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications.

Authors:  Jiezhong Chen
Journal:  World J Virol       Date:  2012-12-12

Review 2.  Experimental and theoretical studies of emodin interacting with a lipid bilayer of DMPC.

Authors:  Antonio R da Cunha; Evandro L Duarte; Hubert Stassen; M Teresa Lamy; Kaline Coutinho
Journal:  Biophys Rev       Date:  2017-09-22

3.  Sensitive and robust UPLC-MS/MS method to determine the gender-dependent pharmacokinetics in rats of emodin and its glucuronide.

Authors:  Wei Liu; Zhijie Zheng; Xi Liu; Song Gao; Ling Ye; Zhen Yang; Ming Hu; Zhongqiu Liu
Journal:  J Pharm Biomed Anal       Date:  2010-12-09       Impact factor: 3.935

4.  Species and gender differences affect the metabolism of emodin via glucuronidation.

Authors:  Wei Liu; Lan Tang; Ling Ye; Zheng Cai; Bijun Xia; Jiajie Zhang; Ming Hu; Zhongqiu Liu
Journal:  AAPS J       Date:  2010-05-14       Impact factor: 4.009

5.  Three-dimensional multispecies nonlinear tumor growth-II: Tumor invasion and angiogenesis.

Authors:  Hermann B Frieboes; Fang Jin; Yao-Li Chuang; Steven M Wise; John S Lowengrub; Vittorio Cristini
Journal:  J Theor Biol       Date:  2010-03-18       Impact factor: 2.691

6.  Nonlinear modelling of cancer: bridging the gap between cells and tumours.

Authors:  J S Lowengrub; H B Frieboes; F Jin; Y-L Chuang; X Li; P Macklin; S M Wise; V Cristini
Journal:  Nonlinearity       Date:  2010

Review 7.  Membrane Dynamics in Health and Disease: Impact on Cellular Signalling.

Authors:  Pranav Adhyapak; Shobhna Kapoor
Journal:  J Membr Biol       Date:  2019-08-21       Impact factor: 1.843

8.  Computer simulation of glioma growth and morphology.

Authors:  Hermann B Frieboes; John S Lowengrub; S Wise; X Zheng; Paul Macklin; Elaine L Bearer; Vittorio Cristini
Journal:  Neuroimage       Date:  2007-03-23       Impact factor: 6.556

9.  Involvement of matrix metalloproteinases on the inhibition of cells invasion and migration by emodin in human neuroblastoma SH-SY5Y cells.

Authors:  Hsu-Feng Lu; Kuang-Chi Lai; Shu-Chun Hsu; Hui-Ju Lin; Chao-Lin Kuo; Ching-Lung Liao; Jai-Sing Yang; Jing-Gung Chung
Journal:  Neurochem Res       Date:  2009-03-17       Impact factor: 3.996

10.  Carcinogen-altered genes in rat esophagus positively modulated to normal levels of expression by both black raspberries and phenylethyl isothiocyanate.

Authors:  Gary D Stoner; Alan A Dombkowski; Rashmeet K Reen; Daniela Cukovic; Sridevi Salagrama; Li-Shu Wang; John F Lechner
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.